Weekly Digest - October 2026

Weekly Digest - October 2026

14 October 2026: Alentis and PinotBio partnered to develop next-generation CLDN1-targeting ADCs

  • Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop next-generation claudin-1-targeted antibody–drug conjugates, combining Alentis’ antibody portfolio with PinotBio’s proprietary linker and payload technologies to expand treatment opportunities across multiple cancer types
  • Under the agreement, Alentis will have an exclusive option to in-license novel linkers and/or payloads from PinotBio for selected development candidates. PinotBio will receive an upfront payment, development, regulatory and commercial milestone payments, and royalties on net sales for each ADC Alentis elects to develop
  • The collaboration aims to address unmet needs across CLDN1-expressing solid tumors, as CLDN1 is overexpressed in more than ten tumor types. The partners intend to develop ADCs with improved efficacy and specificity while addressing treatment resistance and toxicity limitations associated with existing ADC approaches
  • The partnership combines Alentis’ CLDN1-targeting antibody portfolio with PinotBio’s PINOT-ADC platform, which uses novel payloads and tandem-cleavable linkers designed to enhance tumor-cell killing while reducing premature payload release and systemic toxicity
  • Strategically, the collaboration strengthens Alentis’ next-generation ADC pipeline while expanding the application of PinotBio’s linker–payload platform beyond its existing programs. It builds on prior research in which the companies explored dozens of ADC constructs and creates opportunities to develop differentiated CLDN1-targeted candidates across multiple solid tumors

For full story click  here

Share this